Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 11:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 11,175 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Arm 3 Clear all
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

The Effects of Atomoxetine on Cognition and Brain Function Based on Catechol-O-methyltransferase(COMT) Genotype

NCT00548327
View directory record Official record
Conditions
Schizophrenia, Memory Disorders, Cognition Disorders
Interventions
Atomoxetine, Functional magnetic resonance imaging, Neuropsychological Testing, Placebo
Drug · Procedure
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 45 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 14, 2013 · Synced Oct 19, 2026, 11:10 PM EDT
Terminated Phase 2 Interventional Results available

Irinotecan/Cisplatin, Potentially Curative Surgery With or Without Floxuridine, Followed by Capecitabine for Stomach and Gastro-esophageal Junction (GEJ) Cancers

NCT00848783
View directory record Official record
Conditions
Gastric Cancer, Gastric Adenocarcinoma, Esophageal Cancer
Interventions
Irinotecan, Cisplatin, Surgery, Floxuridine, Capecitabine
Drug · Procedure
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
3
States / cities
Los Angeles, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 8, 2018 · Synced Oct 19, 2026, 11:10 PM EDT
Not yet recruiting Not applicable Interventional

EEG-Guided Transcranial Magnetic Stimulation for Adults With Depression

NCT07862205
View directory record Official record
Conditions
Major Depressive Disorder (MDD), Treatment Resistant Depression, Major Depression
Interventions
MagVenture TMS Therapy System with Localite Navigation System and actiCHamp EEG
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
22 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 19, 2026, 11:10 PM EDT
Recruiting Not applicable Interventional

Emovi 3D Knee Assessment Device Intervention for Operational Readiness

NCT06517056
View directory record Official record
Conditions
Patellofemoral Pain, Patellofemoral Pain Syndrome
Interventions
Emovi Knee Kinesiography
Device
Lead sponsor
Womack Army Medical Center
Federal
Eligibility
18 Years to 50 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
Honolulu, Hawaii • Fort Liberty, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Oct 19, 2026, 11:10 PM EDT
Completed Phase 2 Interventional

Diabetic Peripheral Neuropathic Pain (DPNP)

NCT01314222
View directory record Official record
Conditions
Diabetic Peripheral Neuropathic Pain
Interventions
BMS-954561, Pregabalin, Placebo matching BMS-954561, Placebo matching Pregabalin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 85 Years
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
21
States / cities
Birmingham, Alabama • Phoenix, Arizona • Lomita, California + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2015 · Synced Oct 19, 2026, 11:10 PM EDT
Withdrawn Phase 2 Interventional

Safety and Effectiveness Study of CPI-613 and/or Gemcitabine to Treat Metastatic Pancreatic Cancer

NCT01830322
View directory record Official record
Conditions
Metastatic Pancreatic Adenocarcinoma
Interventions
CPI-613, Gemcitabine, Any non-gemcitabine chemotherapies or best supportive care
Drug
Lead sponsor
Cornerstone Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
2
States / cities
The Bronx, New York • Temple, Texas
Source: ClinicalTrials.gov public record
Updated Aug 14, 2013 · Synced Oct 19, 2026, 11:10 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Limb Cooling in Essential Tremor

NCT02067702
View directory record Official record
Conditions
Essential Tremor
Interventions
Limb Cooling Assessment of ET
Procedure
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 95 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 18, 2019 · Synced Oct 19, 2026, 11:10 PM EDT
Completed Phase 3 Interventional Results available

Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma

NCT00336024
View directory record Official record
Conditions
Anaplastic Medulloblastoma, Medulloblastoma, Supratentorial Embryonal Tumor, Not Otherwise Specified, Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Carboplatin, Cisplatin, Cyclophosphamide, Etoposide, Filgrastim, Laboratory Biomarker Analysis, Leucovorin Calcium, Methotrexate, Quality-of-Life Assessment, Thiotepa, Vincristine Sulfate
Procedure · Drug · Biological + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 2 Years
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2025
U.S. locations
129
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 100 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 19, 2026, 11:10 PM EDT
Completed Phase 3 Interventional

A Study to Assess the Efficacy and Safety of 20, 40, and 80mg of Sildenafil Three Times a Day in the Treatment of Pulmonary Arterial Hypertension

NCT00644605
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
sildenafil, placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
24
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Oct 19, 2026, 11:10 PM EDT
Completed Phase 1 Interventional

Safety and Tolerability Study of Lu AF11167 After Repeated Dosing in Patients With Schizophrenia

NCT02202213
View directory record Official record
Conditions
Schizophrenia
Interventions
Placebo, Lu AF11167
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 60 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Feb 18, 2015 · Synced Oct 19, 2026, 11:10 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Human Immunodeficiency Virus (HIV)-Infected Subjects

NCT01165203
View directory record Official record
Conditions
Herpes Zoster
Interventions
Herpes Zoster Vaccine GSK1437173A, Placebo
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
5
States / cities
Long Beach, California • San Francisco, California • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2018 · Synced Oct 19, 2026, 11:10 PM EDT
Recruiting Phase 2 Interventional

Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node or Other High Risk Features

NCT06449313
View directory record Official record
Conditions
Non-small Cell Lung Cancer Stage III
Interventions
Cemiplimab-Rwlc
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
3
States / cities
Washington D.C., District of Columbia • St Louis, Missouri • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 19, 2026, 11:10 PM EDT
Completed Not applicable Interventional Results available

TeleQuit Smoking Cessation Program

NCT00123682
View directory record Official record
Conditions
Smoking
Interventions
Proactive outreach to counseling, Reactive outreach to counseling, Intensive counseling, Self-help
Procedure
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
Not listed
Enrollment
3,120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
3
States / cities
Palo Alto, California • Sepulveda, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 17, 2015 · Synced Oct 19, 2026, 11:10 PM EDT
Completed Phase 2 Interventional Results available

Comparing Pump With Subcutaneous Injection Delivery of PTH 1-34 in the Management of Chronic Hypoparathyroidism

NCT00743782
View directory record Official record
Conditions
Hypoparathyroidism, Hypocalcemia, Autoimmune Polyendocrine Syndrome Type 1, Autosomal Dominant Hypocalcemia Type 1 (ADH1)
Interventions
Synthetic Human Parathyroid Hormone 1-34 pump
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
7 Years to 70 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 19, 2026, 11:10 PM EDT
Terminated Phase 3 Interventional Results available

A Prospective Controlled Treatment Trial for Post-Traumatic Headaches

NCT03007420
View directory record Official record
Conditions
Post-Traumatic Headaches
Interventions
Occipital Nerve Block (ONB) using lidocaine and dexamethosone, Cervical Medial Branch Block (CMBB) using lidocaine and dexamethosone
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
14 Years to 45 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 19, 2026, 11:10 PM EDT
Active, not recruiting Phase 2 Interventional

177-Lutetium-PSMA Before Stereotactic Body Radiotherapy for the Treatment of Oligorecurrent Prostate Cancer, The LUNAR Study

NCT05496959
View directory record Official record
Conditions
Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma, Recurrent Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Lutetium Lu-177 PNT2002, Quality-of-Life Assessment, Stereotactic Body Radiation Therapy
Drug · Other · Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2033
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 19, 2026, 11:10 PM EDT
Terminated Phase 2 Interventional

A Study to Evaluate Safinamide's Effect on Dopamine and Serotonin's Availability by Using Brain Imaging

NCT01264861
View directory record Official record
Conditions
Parkinson Disease
Interventions
Safinamide
Drug
Lead sponsor
Newron Pharmaceuticals SPA
Industry
Eligibility
40 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 18, 2017 · Synced Oct 19, 2026, 11:10 PM EDT
Terminated Phase 3 Interventional Results available

Buspirone as a Potential Treatment for Recurrent Central Apnea

NCT00746954
View directory record Official record
Conditions
Central Apnea, Heart Failure
Interventions
Acetazolamide, Buspirone
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
40 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 14, 2016 · Synced Oct 19, 2026, 11:10 PM EDT
Recruiting Phase 3 Interventional

Efficacy and Safety of Mibavademab in Adult and Pediatric Patients With Generalized Lipodystrophy

NCT07220785
View directory record Official record
Conditions
Generalized Lipodystrophy
Interventions
Mibavademab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
2 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Ann Arbor, Michigan • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 19, 2026, 11:10 PM EDT
Completed Phase 3 Interventional Results available

A Research Study in Children With a Low Level of Hormone to Grow. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day (REAL4)

NCT03811535
View directory record Official record
Conditions
Growth Hormone Deficiency in Children
Interventions
Somapacitan, Norditropin®
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
Up to 11 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
27
States / cities
Birmingham, Alabama • Los Angeles, California • Madera, California + 24 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 19, 2026, 11:10 PM EDT
Completed Phase 2 Interventional

A Study of Enicepatide (CT-388) in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity

NCT06525935
View directory record Official record
Conditions
Obesity, Overweight
Interventions
Placebo, Enicepatide
Drug
Lead sponsor
Carmot Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
469 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
34
States / cities
Birmingham, Alabama • Homewood, Alabama • Mesa, Arizona + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 19, 2026, 11:10 PM EDT
Terminated Not applicable Interventional Results available

Checkpoint Inhibitor and Radiation Therapy in Bulky, Node-Positive Bladder Cancer

NCT04779489
View directory record Official record
Conditions
Bladder Cancer
Interventions
personalized ultrafractionated stereotactic ablative radiotherapy
Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 6, 2024 · Synced Oct 19, 2026, 11:10 PM EDT
Completed Not applicable Interventional Results available

Bioprosthetic or Native Aortic Scallop Intentional Laceration to Prevent Iatrogenic Coronary Artery Obstruction (BASILICA) Prospective Investigation

NCT03381989
View directory record Official record
Conditions
Native and Valve in Valve Aortic Valve Failure
Interventions
ASHI_INTECC Astato XS 20 0.014 guidewire
Device
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
21 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Atlanta, Georgia • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2021 · Synced Oct 19, 2026, 11:10 PM EDT
Withdrawn Phase 2 Interventional

Relapse Prevention Study in Newly Abstinent Smokers

NCT00793468
View directory record Official record
Conditions
Substance Dependence
Interventions
GSK598809, Nicotine Replacement Transdermal Patch, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
10
States / cities
DeLand, Florida • Pembroke Pines, Florida • Stockbridge, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2016 · Synced Oct 19, 2026, 11:10 PM EDT